• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Director Cochran Jennifer R. bought $45,600 worth of shares (30,000 units at $1.52), increasing direct ownership by 26% to 145,274 units (SEC Form 4)

    5/15/25 4:02:17 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $OABI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Cochran Jennifer R.

    (Last) (First) (Middle)
    5980 HORTON STREET, STE 600

    (Street)
    EMERYVILLE CA 94608

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    OmniAb, Inc. [ OABI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/15/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/15/2025 P 30,000 A $1.52(1) 145,274 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.51 to $1.52. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
    Remarks:
    By: /s/ Charles S. Berkman, Attorney-in-Fact For: Jennifer R. Cochran 05/15/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $OABI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OABI

    DatePrice TargetRatingAnalyst
    11/29/2023$6.00Outperform
    RBC Capital Mkts
    4/21/2023$8.00Buy
    The Benchmark Company
    4/13/2023$10.00Buy
    Craig Hallum
    2/22/2023$10.00Outperform
    Cowen
    2/13/2023$11.00Buy
    H.C. Wainwright
    More analyst ratings

    $OABI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by OmniAb Inc.

      SC 13G/A - OmniAb, Inc. (0001846253) (Subject)

      11/14/24 4:06:53 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SC 13D/A filed by OmniAb Inc.

      SC 13D/A - OmniAb, Inc. (0001846253) (Subject)

      7/2/24 5:00:16 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $OABI
    Financials

    Live finance-specific insights

    See more
    • OmniAb Reports First Quarter 2025 Financial Results and Business Highlights

      Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three months ended March 31, 2025, and provided operating and partner program updates. "We have started the year with robust deal flow, including both platform and asset-based deals. Our business remains strong as our diversified pipeline of partner programs is progressing with recent and expected new clinical entrants and data readouts," said Matt Foehr, Chief Executive Officer of OmniAb. "Today we announced the xPloration® Partner Access Program for OmniAb partners, enhancing the scalability of our technology platforms and creating new business opportuni

      5/8/25 4:06:00 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • OmniAb to Report First Quarter 2025 Financial Results on May 8

      OmniAb, Inc. (NASDAQ:OABI) will report financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on Thursday, May 8, 2025, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What:   OmniAb conference call to discuss first quarter 2025 financial results and business updates       Date:   Thursday, May 8, 2025       Time:   4:30 p.m. Eastern time (1:30 p.m. Pacific time)       Phone:   U.S. (800) 549 8228     International (289) 819 1520     Conference ID is 96760    

      4/14/25 8:00:00 AM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

      Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and 12 months ended December 31, 2024, and provided operating and partner program updates. "2024 was a remarkable year featuring double-digit percentage growth in the number of both active partners and programs. Clinical-stage programs advanced well, and we launched new technologies and enhancements that strengthened our platform and expanded our reach," said Matt Foehr, Chief Executive Officer of OmniAb. "We exceeded our internal goals for key metrics and continued to build momentum while optimizing the scalability of our business. We believe our co

      3/18/25 4:05:00 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $OABI
    Leadership Updates

    Live Leadership Updates

    See more
    • OmniAb Appoints Steve Love to its Board of Directors

      OmniAb, Inc. (NASDAQ:OABI) today announced the appointment of Steve Love to its Board of Directors. Mr. Love has more than 30 years of financial experience including more than 13 years serving in Chief Financial Officer positions, and will serve on OmniAb's Audit Committee as Chair. With this appointment the OmniAb Board returns to seven directors, including five independent directors. "We are delighted Steve has agreed to join the OmniAb Board of Directors and extend a warm welcome," stated John Higgins, OmniAb Board Chair. "Steve's vast financial expertise, technical knowledge and experience leading technology and biotechnology companies will be valuable assets as we grow and expand our

      11/1/23 9:00:00 AM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $OABI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RBC Capital Mkts initiated coverage on OmniAb with a new price target

      RBC Capital Mkts initiated coverage of OmniAb with a rating of Outperform and set a new price target of $6.00

      11/29/23 7:31:15 AM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • The Benchmark Company initiated coverage on OmniAb with a new price target

      The Benchmark Company initiated coverage of OmniAb with a rating of Buy and set a new price target of $8.00

      4/21/23 7:43:22 AM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Craig Hallum initiated coverage on OmniAb with a new price target

      Craig Hallum initiated coverage of OmniAb with a rating of Buy and set a new price target of $10.00

      4/13/23 9:08:06 AM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $OABI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OmniAb Reports First Quarter 2025 Financial Results and Business Highlights

      Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three months ended March 31, 2025, and provided operating and partner program updates. "We have started the year with robust deal flow, including both platform and asset-based deals. Our business remains strong as our diversified pipeline of partner programs is progressing with recent and expected new clinical entrants and data readouts," said Matt Foehr, Chief Executive Officer of OmniAb. "Today we announced the xPloration® Partner Access Program for OmniAb partners, enhancing the scalability of our technology platforms and creating new business opportuni

      5/8/25 4:06:00 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • OmniAb Introduces the xPloration® Partner Access Program

      High-Throughput Single B-Cell Screening Platform Now Available for Purchase by OmniAb's Partners for Use in Their Own Laboratories OmniAb, Inc. (NASDAQ:OABI) today introduced the launch of the xPloration Partner Access Program, under which current OmniAb partners can purchase the xPloration instrument to significantly enhance their capabilities in antibody discovery and development. xPloration is OmniAb's proprietary, innovative, high-throughput single B-cell screening platform that leverages machine learning and artificial intelligence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508776052/en/ "xPloration has been a core

      5/8/25 4:05:00 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

      ZURICH, SWITZERLAND, May 5, 2025 -- VERAXA Biotech AG ("VERAXA"), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, "Voyager")), announced today a co-discovery alliance with OmniAb, Inc. (NASDAQ:OABI, "OmniAb")) for the development of a novel bispecific antibody drug conjugate ("bsADC") program targeting solid tumors. The collaboration brings together OmniAb's suite of transgenic antibody discovery solutions with VERAXA's proprietary antibody drug conjugate ("ADC") linker technology and conjugation expertise to support next-generation therapeutic discovery. "This partnership brings together two highly co

      5/5/25 1:00:00 AM ET
      $OABI
      $VACH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $OABI
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by OmniAb Inc.

      SCHEDULE 13G/A - OmniAb, Inc. (0001846253) (Subject)

      5/14/25 12:32:07 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 10-Q filed by OmniAb Inc.

      10-Q - OmniAb, Inc. (0001846253) (Filer)

      5/8/25 4:51:53 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • OmniAb Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - OmniAb, Inc. (0001846253) (Filer)

      5/8/25 4:11:02 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $OABI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cochran Jennifer R. bought $45,600 worth of shares (30,000 units at $1.52), increasing direct ownership by 26% to 145,274 units (SEC Form 4)

      4 - OmniAb, Inc. (0001846253) (Issuer)

      5/15/25 4:02:17 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Love Steven bought $36,500 worth of shares (25,000 units at $1.46), increasing direct ownership by 188% to 38,333 units (SEC Form 4)

      4 - OmniAb, Inc. (0001846253) (Issuer)

      5/14/25 5:04:09 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Higgins John L bought $93,600 worth of shares (65,000 units at $1.44), increasing direct ownership by 2% to 2,831,887 units (SEC Form 4)

      4 - OmniAb, Inc. (0001846253) (Issuer)

      5/13/25 5:52:02 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $OABI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cochran Jennifer R. bought $45,600 worth of shares (30,000 units at $1.52), increasing direct ownership by 26% to 145,274 units (SEC Form 4)

      4 - OmniAb, Inc. (0001846253) (Issuer)

      5/15/25 4:02:17 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Love Steven bought $36,500 worth of shares (25,000 units at $1.46), increasing direct ownership by 188% to 38,333 units (SEC Form 4)

      4 - OmniAb, Inc. (0001846253) (Issuer)

      5/14/25 5:04:09 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Higgins John L bought $93,600 worth of shares (65,000 units at $1.44), increasing direct ownership by 2% to 2,831,887 units (SEC Form 4)

      4 - OmniAb, Inc. (0001846253) (Issuer)

      5/13/25 5:52:02 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care